HOME >> BIOLOGY >> NEWS
Disease-resistant papaya saves Hawaiian papaya industry

St. Paul, Minn. (August 20, 2004) A new papaya, genetically resistant to papaya ringspot virus (PRSV), has rescued the Hawaiian papaya industry and may have the potential to do the same in other papaya-growing regions of the world, say plant pathologists with The American Phytopathological Society (APS).

"In 1992, Hawaii's papaya industry faced economic disaster when PRSV was discovered in the Puna District of the Hawaii Island where 95 percent of the state's papaya was grown," said Dennis Gonsalves, plant pathologist with the USDA's Agricultural Research Service at the U.S. Pacific Basin Agricultural Research Center, Hilo, HI. By 1995, PRSV was widespread in Puna and the industry was in a crisis situation. PRSV rapidly spreads when aphids (small insects) pick up the virus on their mouths while feeding on infected plants and continue to feed on healthy plants.

In the late 1980s, plant pathologists began to develop transgenic papayas resistant to PRSV and the disease-resistant papaya was commercially released in May 1998.

"Today, we are proud to say that the transgenic papaya has fulfilled the hope of the Hawaiian papaya industry to control PRSV and to restore the supply of papaya to nearly the level existing before PRSV entered Puna in 1992," said Gonsalves. The resistance of the transgenic papaya allowed farmers to directly reclaim their farms without first clearing their land of all infected papaya trees. The percentage of Hawaii's fresh papaya production produced in Puna has risen from a low of 65 percent in 1999 to 84 percent in 2002.

Since PRSV is a worldwide problem on papaya, other countries have showed interest in developing the technology for their use. "Due to its success, the transgenic papaya has often been referred to as the model for the use of biotechnology to help agriculture," said Gonsalves.

More on this subject can be found in this month's APS feature article at

Contact: Amy Steigman
asteigman@scisoc.org
651-994-3802
American Phytopathological Society
20-Aug-2004


Page: 1 2

Related biology news :

1. Researchers Find How Disease-resistant Plants Recognize Bacteria
2. Trap crop saves Texas cross timbers melon production
3. Salmonella infects cells and saves itself by altering host membrane lipids
4. Busy sequencing technique saves money and time
5. Common asthma drug saves patients money, trips to hospital
6. Want a side of algae with that? Hawaiian farmers sell seaweed by the seashore
7. New study finds evolutionary diversification in Hawaiian spiders
8. Botanists collect, study rare Hawaiian plants
9. Hawaiian chemist honored for ocean research at Pacifichem 2000
10. Hawaiian Whales Show No Overt Response To Sounds Of ATOC Simulation
11. Chemical engineers discover filtration system to help biotech industry

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... (PRWEB) , ... August 25, ... ... clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex ... enrolment in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a ... U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug ... of severe COVID-19. Approval of this IND allows Sentien to initiate a Phase ...
(Date:8/12/2020)... SOUTHFIELD, Mich. (PRWEB) , ... August 11, 2020 ... ... Janssen R&D subsidiary based in Princeton, NJ, have entered into license agreements with ... discovery and development. Both Roche and J&J have annual Research and Development ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... 11, 2020 , ... The FSHD Society announced today that ... Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on funding of ... academic research centers in the United States and Europe with expertise in FSHD ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly regarded CDMO ... the purchase of greenfield for a new, expanded manufacturing facility. The site is ... in the initial acquisition, with an option to purchase an additional 21 acres ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive ... patients may choose which extremities they would like treated. , Several studies have shown ... At R3 International, umbilical cord tissue is obtained from a lab with a long ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... can combine up to three different materials for use with CRM, neurostimulation, vascular, ... to three materials to meet specific design requirements, performance, and cost criteria; especially ...
Breaking Biology Technology:
Cached News: